1 Table of Contents 1 Table of Contents 5 1.1 List of Tables 8 1.2 List of Figures 8 2 Introduction 10 2.1 Disease Introduction 10 2.2 Epidemiology 10 2.3 Symptoms 11 2.4 Etiology and Pathophysiology 13 2.4.1 Pathophysiology 14 2.5 Diagnosis 15 2.6 Disease Stages 17 2.7 Prognosis 19 2.8 Treatment Guidelines and Options 20 2.8.1 Treatment Guidelines 20 2.8.2 National and Local Registries 21 2.9 Treatment Options 22 2.9.1 Treatment Algorithm 22 2.9.2 Pharmacological Treatments 23 2.9.3 Non-Pharmacological Treatments 25 2.9.4 Exercise 25 2.9.5 Dietary Interventions 25 3 Marketed Products 27 3.1 Overview 27 3.2 Bisphosphonates 28 3.2.1 Risedronate - Warner Chilcott 28 3.2.2 Alendronate - Merck & Co. 29 3.2.3 Boniva (ibandronate) - Roche 30 3.2.4 Zoledronic Acid - Novartis 31 3.2.5 Recalbon/Bonoteo (minodronate) - Ono and Astellas Pharma 33 3.2.6 Etidronate - Procter & Gamble and Sumitomo Pharmaceuticals 33 3.3 Dual-Acting Non-Bisphosphonates 34 3.3.1 Strontium Ranelate - Servier 34 3.4 Selective Estrogen Receptor Modulators 35 3.4.1 Evista (raloxifene) - Eli Lilly 35 3.4.2 Viviant (bazedoxifene) - Ligand and Pfizer 36 3.5 Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Inhibitor 38 3.5.1 Prolia/Pralia (denosumab) - Amgen 38 3.6 Calcitonins 39 3.6.1 Calcitonin-salmon 39 3.7 Parathyroid Hormone 40 3.7.1 Forteo (teriparatide) - Eli Lilly 40 3.8 Vitamin D3 Derivative 42 3.8.1 Edirol (eldecalcitol) - Chugai 42 3.9 Comparative Efficacy and Safety of Marketed Products 42 4 Product Pipeline 46 4.1 Overview 46 4.2 Pipeline Distribution by Phase of Development, Molecule Type, Route of Administration and Novelty 47 4.3 Pipeline Distribution by Molecular Target 49 4.4 Promising Pipeline Candidates 52 4.4.1 Evenity (Romosozumab/AMG-785) - Amgen 52 4.4.2 Tymlos - Abaloparatide-SC - Radius Health 55 4.4.3 Uni-PTH - Uni-Bio Science 58 4.5 Comparative Efficacy and Safety of Pipeline Products 60 4.6 Product Competitiveness Framework 60 5 Clinical Trial Analysis 63 5.1 Failure Rate 63 5.1.1 Overall Failure Rate 63 5.1.2 Failure Rate by Phase and Molecule Type 65 5.1.3 Failure Rate by Phase and Molecular Target 65 5.2 Clinical Trial Duration 66 5.2.1 Clinical Trial Duration by Molecule Type 66 5.2.2 Clinical Trial Duration by Molecular Target 67 5.3 Clinical Trial Size 68 5.3.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development 68 5.3.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 71 5.4 Summary of Clinical Trial Metrics 73 6 Multi-Scenario Forecast 74 6.1 Geographical Markets 74 6.2 Asia-Pacific Markets 75 6.3 India 76 6.3.1 Treatment Usage Patterns 76 6.3.2 Annual Cost of Therapy 77 6.3.3 Market Size 78 6.4 China 80 6.4.1 Treatment Usage Patterns 80 6.4.2 Annual Cost of Therapy 82 6.4.3 Market Size 83 6.5 Australia 85 6.5.1 Treatment Usage Patterns 85 6.5.2 Annual Cost of Therapy 85 6.5.3 Market Size 87 6.6 South Korea 89 6.6.1 Treatment Usage Patterns 89 6.6.2 Annual Cost of Therapy 90 6.6.3 Market Size 90 6.7 Japan 92 6.7.1 Treatment Usage Patterns 92 6.7.2 Annual Cost of Therapy 93 6.7.3 Market Size 94 7 Market Dynamics (Drivers and Barriers) of Osteoporosis Therapeutics Market 97 7.1 Drivers 97 7.1.1 Rising Prevalence 97 7.1.2 Increasing Health Insurance Coverage for Aged Population 97 7.1.3 Increasing Public and Policymaker Awareness 97 7.1.4 Promising Late-Stage Pipeline Products can Change the Treatment Paradigm 98 7.2 Barriers 98 7.2.1 Impending Patent Cliffs and Generic Erosion 98 7.2.2 Low Diagnosis and Treatment Rates 99 7.2.3 Non-Availability or Lack of Benefits for Combination Anabolic and Antiresorptive Therapies 99 7.2.4 Competition from Traditional Medicines 99 8 Deals and Strategic Consolidations 100 8.1 Licensing Deals 100 8.1.1 Deals by Region and Value 100 8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 101 8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 101 8.1.4 Key Licensing Deals 104 8.2 Co-development 106 8.2.1 Deals by Region and Value 106 8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 106 8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 107 8.2.4 Key Co-Development Deals 108 9 Appendix 110 9.1 All Pipeline Drugs by Stage of Development 110 9.1.1 Discovery 110 9.1.2 Preclinical 112 9.1.3 Phase I 115 9.1.4 Phase II 116 9.1.5 Phase III 116 9.1.6 Pre-registration 117 9.2 Summary of Multi-scenario Market Forecasts to 2024 117 9.2.1 Asia-Pacific 117 9.2.2 India 118 9.2.3 China 118 9.2.4 Australia 119 9.2.5 South Korea 119 9.2.6 Japan 120 9.3 Bibliography 120 9.4 Abbreviations 132 9.5 Research Methodology 134 9.5.1 Secondary Research 134 9.5.2 Marketed Product Profiles 135 9.5.3 Late-Stage Pipeline Candidates 135 9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 135 9.5.5 Product Competitiveness Framework 135 9.5.6 Pipeline Analysis 136 9.5.7 Clinical Trials 136 9.5.8 Clinical trial Endpoint Analysis 136 9.5.9 Forecasting Model 137 9.5.10 Deals Data Analysis 138 9.6 Contact Us 138 9.7 Disclaimer 138

1.1 List of Tables Table 1: Osteoporosis Therapeutics Market, Classical Case of Osteoporosis with Respect to Age 12 Table 2: Osteoporosis Therapeutics Market, Common Types of Fracture in Osteoporosis 13 Table 3: Osteoporosis Therapeutics Market, Diagnosis Tests for Osteoporosis 16 Table 4: Osteoporosis Therapeutics Market, T-Score Ranges for Determination of BMD 16 Table 5: Osteoporosis Therapeutics Market, Clinical Stage Characteristics 17 Table 6: Osteoporosis Therapeutics Market, Clinical Types of Osteoporosis 17 Table 7: Osteoporosis Therapeutics Market, Characteristics of Type 1 and 2 Primary Osteoporosis 18 Table 8: Osteoporosis Therapeutics Market, Causes of Secondary Osteoporosis 19 Table 9: Osteoporosis Therapeutics Market, Global, Licensing Deals Valued over $10m, 2006-2017 105 Table 10: Osteoporosis Therapeutics Market, Global, All Pipeline Products, Discovery, 2017 110 Table 11: Osteoporosis Therapeutics Market, Global, All Pipeline Products, Preclinical, 2017 112 Table 12: Osteoporosis Therapeutics Market, Global, All Pipeline Products, Phase I, 2017 115 Table 13: Osteoporosis Therapeutics Market, Global, All Pipeline Products, Phase II, 2017 116 Table 14: Osteoporosis Therapeutics Market, Global, All Pipeline Products, Phase III, 2017 116 Table 15: Osteoporosis Therapeutics Market, Global, All Pipeline Products, Pre-registration Phase, 2017 117 Table 16: Osteoporosis Therapeutics Market, Asia-Pacific, Market Forecast, 2017-2024 117 Table 17: Osteoporosis Therapeutics Market, India, Market Forecast, 2017-2024 118 Table 18: Osteoporosis Therapeutics Market, China, Market Forecast, 2017-2024 118 Table 19: Osteoporosis Therapeutics Market, Australia, Market Forecast, 2017-2024 119 Table 20: Osteoporosis Therapeutics Market, South Korea, Market Forecast, 2017-2024 119 Table 21: Osteoporosis Therapeutics Market, Japan, Market Forecast, 2017-2024 1201.2 List of Figures Figure 1: Osteoporosis Therapeutics Market, Indian Osteoporosis Treatment Guidelines, 2013 21 Figure 2: Osteoporosis Therapeutics Market, Treatment Algorithm of Osteoporosis 23 Figure 3: Osteoporosis Therapeutics Market, Comparative Efficacy and Safety Heat Map for Marketed Products for the Treatment of Osteoporosis, 2018 44 Figure 4: Osteoporosis Therapeutics Market, Comparative Efficacy Heat Map for Marketed Products for the Treatment of Osteoporosis in Men, 2018 44 Figure 5: Osteoporosis Therapeutics Market, Comparative Efficacy Heat Map for Marketed Products for the Treatment of Glucocorticoid-Induced Osteoporosis, 2018 45 Figure 6: Osteoporosis Therapeutics Market, Comparative Efficacy Heat Map for Marketed Products for the Prevention of Osteoporosis in Postmenopausal Women, 2018 45 Figure 7: Pipeline for Osteoporosis Therapeutics, Global, 2018 48 Figure 8: Pipeline for Osteoporosis Therapeutics by Molecular Target, Global, 2018 51 Figure 9: Pipeline for Osteoporosis Therapeutics by Molecular Target and Stage of Development, Global, 2018 52 Figure 10: Osteoporosis Therapeutics Market, Asia-Pacific, Romosozumab Market Forecast ($m), 2018-2022 55 Figure 11: Osteoporosis Therapeutics Market, Asia-Pacific, Abaloparatide Market Forecast ($m), 2018-2024 58 Figure 12: Osteoporosis Therapeutics Market, Asia-Pacific, Uni-PTH Market Forecast ($m), 2019-2024 59 Figure 13: Osteoporosis Therapeutics Market, Comparative Efficacy Heat Map for Pipeline Products, 2018 60 Figure 14: Osteoporosis Therapeutics Market, Global, Competitor Matrix for Marketed and Pipeline Products, 2018 62 Figure 15: Osteoporosis Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2017 64 Figure 16: Osteoporosis Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006-2017 65 Figure 17: Osteoporosis Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006-2017 66 Figure 18: Osteoporosis Therapeutics, Global, Clinical Trial Duration by Molecule Type, 2006-2017 67 Figure 19: Osteoporosis Therapeutics, Global, Clinical Trial Duration by Molecular Target, 2006-2017 68 Figure 20: Osteoporosis Therapeutics, Global, Clinical Trial Size per Product by Molecule Type, 2006-2017 69 Figure 21: Osteoporosis Therapeutics, Global, Clinical Trial Size per Product by Molecular Target, 2006-2017 70 Figure 22: Osteoporosis Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type, 2006-2017 71 Figure 23: Osteoporosis Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target, 2006-2017 72 Figure 24: Osteoporosis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 73 Figure 25: Osteoporosis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 73 Figure 26: Osteoporosis Therapeutics Market, Asia-Pacific, Treatment Patterns (million) and Market Size ($bn), 2017-2024 75 Figure 27: Osteoporosis Therapeutics Market, India, Treatment Patterns (million), 2017-2024 77 Figure 28: Osteoporosis Therapeutics Market, India, Annual Cost of Therapy ($), 2017-2024 78 Figure 29: Osteoporosis Therapeutics Market, India, Market Size ($m), 2017-2024 79 Figure 30: Osteoporosis Therapeutics Market, China, Treatment Patterns (million), 2017-2024 81 Figure 31: Osteoporosis Therapeutics Market, China, Annual Cost of Therapy ($), 2017-2024 82 Figure 32: Osteoporosis Therapeutics Market, China, Market Size ($m), 2017-2024 83 Figure 33: Osteoporosis Therapeutics Market, Australia, Treatment Patterns (‘000), 2017-2024 85 Figure 34: Osteoporosis Therapeutics Market, Australia, Annual Cost of Therapy ($), 2017-2024 86 Figure 35: Osteoporosis Therapeutics Market, Australia, Market Size ($m), 2017-2024 87 Figure 36: Osteoporosis Therapeutics Market, South Korea, Treatment Patterns (‘000), 2017-2024 89 Figure 37: Osteoporosis Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2017-2024 90 Figure 38: Osteoporosis Therapeutics Market, South Korea, Market Size ($m), 2017-2024 91 Figure 39: Osteoporosis Therapeutics Market, Japan, Treatment Patterns (million), 2017-2024 93 Figure 40: Osteoporosis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2017-2024 94 Figure 41: Osteoporosis Therapeutics Market, Japan, Market Size ($m), 2017-2024 95 Figure 42: Osteoporosis Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2017 100 Figure 43: Osteoporosis Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2017 101 Figure 44: Osteoporosis Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017 102 Figure 45: Osteoporosis Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2017 103 Figure 46: Osteoporosis Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2017 103 Figure 47: Osteoporosis Therapeutics Market, Global, Co-development Deals by Region, 2006-2017 106 Figure 48: Osteoporosis Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2017 106 Figure 49: Osteoporosis Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017 107 Figure 50: Osteoporosis Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2006-2017 108 Figure 51: Osteoporosis Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2017 108